Vasiliki Symeonidou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vasiliki Symeonidou has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
Aimee E. Jackson
Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK
1 shared publication- Alessandro Raveane
Department of Biology and Biotechnology ‘L. Spallanzani’, University of Pavia, via Ferrata 9, 27100 Pavia, Italy
1 shared publication - Alice Giustacchini
Genomics Research Centre, Human Technopole, Milan, Italy
1 shared publication - Ana-Maria Cujba
Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK
1 shared publication Andrea Senacheribbe
Division of Computational Genomics and Systems Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
1 shared publicationAndrei Cristea
Fondazione Human Technopole, Via Levi Montalcini 1, 20157 Milano, Italy
1 shared publication
Latest Publications
- Open Access
Multimodal population-scale cell atlases define archetypes and extremes of human blood
The cellular composition of blood is fundamental to human physiology and is routinely measured to assess health and disease. Circulating immune cells show extensive heterogeneity, but the organising principles and extremes of variation across individuals remain undefined. Here, using single-cell transcriptomics across two biobank cohorts encompassing ~6,000 individuals, we show that human blood occupies recurrent archetypal states defined by coordinated cell composition patterns. We delineate three major archetypes spanning naive lymphoid, myeloid and cytotoxic composition, and two minor archetypes characterised by type I interferon-driven inflammation and expanded premalignant CD5+ B cells. We develop cell2clone to infer lymphocyte clonal expansions, revealing how reactive clonal processes drive the cytotoxic archetype and premalignant clonal expansion establishes the CD5+ B cell archetype, creating outlier states that uncover context-specific effects of germline variants. Clonal haematopoiesis and mosaic chromosomal alterations influence blood states in an archetype-dependent manner. The archetype framework links blood states to common disease risk and clinical blood counts and, through a machine-learning model ArcheTypist, classifies infection and cancer immunotherapy outcomes. This population-scale framework has implications for diagnostics, early disease detection, immunotherapy stratification and mechanistic insights into disease susceptibility and therapy response, providing an organising model for identifying compositional subtypes across human tissues.
Open AccessMultimodal population-scale cell atlases define archetypes and extremes of human blood
The cellular composition of blood is fundamental to human physiology and is routinely measured to assess health and disease. Circulating immune cells show extensive heterogeneity, but the organising principles and extremes of variation across individuals remain undefined. Here, using single-cell transcriptomics across two biobank cohorts encompassing ~6,000 individuals, we show that human blood occupies recurrent archetypal states defined by coordinated cell composition patterns. We delineate three major archetypes spanning naive lymphoid, myeloid and cytotoxic composition, and two minor archetypes characterised by type I interferon-driven inflammation and expanded premalignant CD5+ B cells. We develop cell2clone to infer lymphocyte clonal expansions, revealing how reactive clonal processes drive the cytotoxic archetype and premalignant clonal expansion establishes the CD5+ B cell archetype, creating outlier states that uncover context-specific effects of germline variants. Clonal haematopoiesis and mosaic chromosomal alterations influence blood states in an archetype-dependent manner. The archetype framework links blood states to common disease risk and clinical blood counts and, through a machine-learning model ArcheTypist, classifies infection and cancer immunotherapy outcomes. This population-scale framework has implications for diagnostics, early disease detection, immunotherapy stratification and mechanistic insights into disease susceptibility and therapy response, providing an organising model for identifying compositional subtypes across human tissues.
- Open Access
Heterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
Acute myeloid leukaemia is prevalent in older patients that are often ineligible for intensive chemotherapy and treatment options remain limited with azacitidine being at the forefront. Azacitidine has been used in the clinic for decades, however, we still lack a complete understanding of the mechanisms by which the drug exerts its anti‐tumour effect. To gain insight into the mechanism of action, we defined the mutational profile of sequential samples of patients treated with azacitidine. We did not identify any mutations that could predict response and observed lack of a uniform pattern of clonal evolution. Focusing on responders, at remission, we observed three types of response: (1) an almost complete elimination of mutations (33%), (2) no change (17%), and (3) change with no discernible pattern (50%). Heterogeneous patterns were also observed at relapse, with no clonal evolution between remission and relapse in some patients. Lack of clonal evolution suggests that non‐genetic mechanisms might be involved. Towards understanding such mechanisms, we investigated the immune microenvironment in a number of patients and we observed lack of a uniform response following therapy. We identified a higher frequency of cytotoxic T cells in responders and higher frequency of naïve helper T cells in non‐responders.
Open AccessHeterogeneous genetic and non‐genetic mechanisms contribute to response and resistance to azacitidine monotherapy
Acute myeloid leukaemia is prevalent in older patients that are often ineligible for intensive chemotherapy and treatment options remain limited with azacitidine being at the forefront. Azacitidine has been used in the clinic for decades, however, we still lack a complete understanding of the mechanisms by which the drug exerts its anti‐tumour effect. To gain insight into the mechanism of action, we defined the mutational profile of sequential samples of patients treated with azacitidine. We did not identify any mutations that could predict response and observed lack of a uniform pattern of clonal evolution. Focusing on responders, at remission, we observed three types of response: (1) an almost complete elimination of mutations (33%), (2) no change (17%), and (3) change with no discernible pattern (50%). Heterogeneous patterns were also observed at relapse, with no clonal evolution between remission and relapse in some patients. Lack of clonal evolution suggests that non‐genetic mechanisms might be involved. Towards understanding such mechanisms, we investigated the immune microenvironment in a number of patients and we observed lack of a uniform response following therapy. We identified a higher frequency of cytotoxic T cells in responders and higher frequency of naïve helper T cells in non‐responders.